Skip to Content

Liposomal Daunorubicin-Cytarabine (Vyxeos®) Management

Download PQI pdf 0.22MB

Last Updated: September 2, 2023

By: Anna Howard, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss the option of using liposomal daunorubicin-cytarabine for patients with newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasiarelated changes (AML-MRC). 1

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI